Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: DMY001
MIFTS: 46

Demyelinating Polyneuropathy

Categories: Neuronal diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Demyelinating Polyneuropathy

About this section

MalaCards integrated aliases for Demyelinating Polyneuropathy:

Name: Demyelinating Polyneuropathy 12 15
Peripheral Demyelinating Neuropathy 12 73

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Neuronal diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:5214
NCIt 50 C27062
SNOMED-CT 68 23414001
UMLS 73 C0270922
Sources

Summaries for Demyelinating Polyneuropathy

About this section
MalaCards based summary : Demyelinating Polyneuropathy, also known as peripheral demyelinating neuropathy, is related to chronic inflammatory demyelinating polyneuropathy and guillain-barre syndrome. An important gene associated with Demyelinating Polyneuropathy is PMP22 (Peripheral Myelin Protein 22), and among its related pathways/superpathways are Neuroscience and L1CAM interactions. The drugs Rho(D) Immune Globulin and gamma-Globulins have been mentioned in the context of this disorder. Affiliated tissues include t cells, spinal cord and b cells, and related phenotypes are behavior/neurological and homeostasis/metabolism

Sources

Related Diseases for Demyelinating Polyneuropathy

About this section

Diseases in the Demyelinating Polyneuropathy family:

Chronic Inflammatory Demyelinating Polyneuropathy Subacute Inflammatory Demyelinating Polyneuropathy

Diseases related to Demyelinating Polyneuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 239)
# Related Disease Score Top Affiliating Genes
1 chronic inflammatory demyelinating polyneuropathy 33.4 AIF1 CNTN2 HP NFASC TTR
2 guillain-barre syndrome 32.4 ALB HP PMP22
3 polyneuropathy 32.1 MAG PMP22 TTR
4 multifocal motor neuropathy 30.7 CNTN2 FCGR2B
5 hereditary neuropathies 30.4 MAG PMP22
6 chronic inflammatory demyelinating polyradiculoneuropathy 30.0 ALB PMP22
7 sensory peripheral neuropathy 29.3 MAG NGF PMP22
8 polyradiculoneuropathy 29.2 ALB MAG NFASC PMP22
9 peripheral nervous system disease 28.6 MAG NGF PMP22 TTR
10 peripheral demyelinating neuropathy, central dysmyelination, waardenburg syndrome, and hirschsprung disease 12.6
11 subacute inflammatory demyelinating polyneuropathy 12.2
12 guillain-barre syndrome, familial 11.9
13 lewis-sumner syndrome 11.3
14 charcot-marie-tooth disease, axonal, type 2e 11.2
15 canomad syndrome 11.0
16 charcot-marie-tooth disease, demyelinating, type 1b 11.0
17 charcot-marie-tooth disease, axonal, type 2a1 11.0
18 charcot-marie-tooth disease, demyelinating, type 1a 11.0
19 charcot-marie-tooth disease and deafness 11.0
20 charcot-marie-tooth disease, type 4a 11.0
21 charcot-marie-tooth disease, x-linked dominant, 6 11.0
22 charcot-marie-tooth disease, x-linked dominant, 1 11.0
23 charcot-marie-tooth disease, x-linked recessive, 5 11.0
24 charcot-marie-tooth disease, axonal, type 2b 11.0
25 charcot-marie-tooth disease, demyelinating, type 1c 11.0
26 neuropathy, hereditary motor and sensory, type via 11.0
27 charcot-marie-tooth disease, type 4b1 11.0
28 charcot-marie-tooth disease, type 4d 11.0
29 charcot-marie-tooth disease, axonal, type 2d 11.0
30 charcot-marie-tooth disease, type 4c 11.0
31 charcot-marie-tooth disease, type 4b2 11.0
32 charcot-marie-tooth disease, axonal, type 2b1 11.0
33 charcot-marie-tooth disease, axonal, type 2b2 11.0
34 charcot-marie-tooth disease, dominant intermediate b 11.0
35 charcot-marie-tooth disease, axonal, type 2f 11.0
36 charcot-marie-tooth disease, axonal, type 2i 11.0
37 charcot-marie-tooth disease, demyelinating, type 1d 11.0
38 charcot-marie-tooth disease, demyelinating, type 1f 11.0
39 charcot-marie-tooth disease, axonal, type 2j 11.0
40 charcot-marie-tooth disease, axonal, type 2k 11.0
41 charcot-marie-tooth disease, axonal, type 2l 11.0
42 charcot-marie-tooth disease, axonal, autosomal dominant, type 2a2a 11.0
43 charcot-marie-tooth disease, type 4h 11.0
44 charcot-marie-tooth disease, axonal, type 2n 11.0
45 charcot-marie-tooth disease, axonal, type 2p 11.0
46 charcot-marie-tooth disease, demyelinating, type 4f 11.0
47 charcot-marie-tooth disease, axonal, type 2r 11.0
48 charcot-marie-tooth disease, type 4k 11.0
49 charcot-marie-tooth disease, axonal, type 2t 11.0
50 nerve compression syndrome 10.6 PMP22 TTR

Graphical network of the top 20 diseases related to Demyelinating Polyneuropathy:



Diseases related to Demyelinating Polyneuropathy
Sources

Symptoms & Phenotypes for Demyelinating Polyneuropathy

About this section

MGI Mouse Phenotypes related to Demyelinating Polyneuropathy:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.91 PMP22 APOA4 PTGDS CNTN1 CNTN2 FCGR2B
2 homeostasis/metabolism MP:0005376 9.9 APOA4 PTGDS TTR FCGR2B HP MAG
3 mortality/aging MP:0010768 9.61 PMP22 APOA4 PTGDS CNTN1 FCGR2B HP
4 nervous system MP:0003631 9.32 APOA4 PTGDS CNTN1 CNTN2 FCGR2B MAG
Sources

Drugs & Therapeutics for Demyelinating Polyneuropathy

About this section

Drugs for Demyelinating Polyneuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 46)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Rho(D) Immune Globulin Phase 4,Phase 3,Phase 2,Not Applicable
2 gamma-Globulins Phase 4,Phase 3,Phase 2,Not Applicable
3 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
4 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
5 Immunoglobulins, Intravenous Phase 4,Phase 3,Phase 2,Not Applicable
6
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
7
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
8
Glycine Approved, Nutraceutical, Vet_approved Phase 3 56-40-6 750
9 tannic acid Approved, Nutraceutical Phase 3
10 glucocorticoids Phase 3
11 3,4-diaminopyridine Phase 3
12 Hormone Antagonists Phase 3,Phase 2
13 Hormones Phase 3,Phase 2
14 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2
15 Immunoglobulin G Phase 3,Not Applicable
16 Potassium Channel Blockers Phase 3
17 Anti-Inflammatory Agents Phase 3
18 Antineoplastic Agents, Hormonal Phase 3
19 Pharmaceutical Solutions Phase 3
20
rituximab Approved Phase 2 174722-31-7 10201696
21
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
22 Micronutrients Phase 2
23 Thioctic Acid Phase 2
24 Trace Elements Phase 2
25 Vitamin B Complex Phase 2
26 Vitamins Phase 2
27 Antibodies, Monoclonal Phase 2
28 Antioxidants Phase 2
29 Protective Agents Phase 2
30 Antirheumatic Agents Phase 2
31 Fibrinolytic Agents Phase 2
32 Tissue Plasminogen Activator Phase 2
33 Plasminogen Phase 2
34 Folate Nutraceutical Phase 2
35 Alpha-lipoic Acid Nutraceutical Phase 2
36 Vitamin B9 Nutraceutical Phase 2
37 interferons
38 Adjuvants, Immunologic
39 Anti-Bacterial Agents
40 Antibiotics, Antitubercular
41 Anti-Infective Agents
42 Interferon Inducers
43 Krestin
44 Radiation-Protective Agents
45 Antiviral Agents
46 Antibodies, Anti-Idiotypic Not Applicable

Interventional clinical trials:

(show all 40)
# Name Status NCT ID Phase Drugs
1 IVIg for Demyelination in Diabetes Mellitus Recruiting NCT02372149 Phase 4 10% intravenous immunoglobulin (IVIg);0.9% sodium chloride
2 MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study Active, not recruiting NCT03226119 Phase 4
3 Alemtuzumab in Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIPD) Withdrawn NCT01757574 Phase 4 Alemtuzumab infusion
4 Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Chronic Inflammatory Demyelinating Polyneuropathy. Completed NCT01824251 Phase 3 NPB-01
5 Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT01184846 Phase 3
6 Randomized Open-label Trial to Compare Efficacy and Tolerance of Corticosteroids and IVIg Completed NCT01349270 Phase 3 Immunoglobulin perfusion;Prednisone
7 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20) Completed NCT01545076 Phase 3
8 Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT02027701 Phase 3
9 Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT00220740 Phase 3 Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified;Albumin (Human) 25%, United States Pharmacopeia (USP)
10 Phase III Randomized, Double-Blind, Placebo-Controlled Study of 3,4-Diaminopyridine for Demyelinating Polyneuropathy Completed NCT00004939 Phase 3 ,4-diaminopyridine
11 Phase III Randomized, Double-Blind, Placebo-Controlled Study of Intravenous Immune Globulin for Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT00004772 Phase 3 Immune globulin
12 Phase III Multicenter Double Blind Controlled Trial of Human Immune Globulin Therapy in Previously Untreated Patients With Chronic Inflammatory Demyelinating Neuropathy Completed NCT00004286 Phase 3 immune globulin
13 Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) Neuropathy Recruiting NCT02638207 Phase 3 NewGam
14 Panzyga in CIDP Administered at Different Infusion Rates Not yet recruiting NCT03166527 Phase 3 Immune Globulin 10% Intravenous Solution
15 Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy Completed NCT00962429 Phase 2 lipoic acid
16 Intravenous Immunoglobulin (IVIg) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Completed NCT00001287 Phase 2 intravenous immunoglobulin (IVIg)
17 Rituximab to Treat Neuropathy With Anti-MAG Antibodies Completed NCT00050245 Phase 2 Rituximab
18 SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study Recruiting NCT02967679 Phase 1, Phase 2 MD1003
19 Stem Cell Transplantation for Stiff Person Syndrome (SPS) Recruiting NCT02282514 Phase 1, Phase 2 Cyclophosphamide;Mesna;rATG;Methylprednisolone;G-CSF;Rituxan
20 Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy Active, not recruiting NCT00278629 Phase 2
21 Thrombolysis in Ischemic Spinal Cord Stroke Active, not recruiting NCT02242084 Phase 2 Intravenuse Alteplase
22 High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating Polyneuropathy Withdrawn NCT01236456 Phase 2 Cyclophosphamide
23 Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy Withdrawn NCT02574962 Phase 2 H.P. Acthar® Gel
24 Effects of an Intervention Program by Proprioceptive Neuromuscular Facilitation, in Muscle Force Irradiation. Unknown status NCT02255708 Phase 1
25 Prevalence of Decreased Corneal Sensation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy Unknown status NCT01379833
26 sCD163 & CD19 as Candidate Biomarkers in CIDP and MMN Unknown status NCT02271724
27 sCD163 as a Potential Biomarker in Guillain- Barré Syndrome Unknown status NCT02582853
28 Effect of Resistance and Aerobic Exercise in CIDP or MMN Completed NCT02121678 Not Applicable
29 Prevalence of Genetic Mutations in Patients With Neuropathy Associated With Anti-Myelin-associated Glycoprotein (MAG) Antibodies Completed NCT03268161
30 Diffusion Tensor Imaging in Chronic Inflammatory Demyelinating Polyneuropathy (PIDC) Completed NCT03460951
31 Immunoglobulin Dosage and Administration Form in CIDP and MMN Completed NCT02111590 Immunoglobulins
32 Study Assessing Risk of Autoimmune Diseases in Females (9 - 25 Years) Exposed to Cervarix® in United Kingdom Completed NCT01953822
33 Magnetic Resonance Diagnostics of Diabetic Peripheral Neuropathy Completed NCT01847937
34 Early Diagnosis of TTR Amyloidosis by Use of Molecular Biology Recruiting NCT03373370
35 Low Level Laser Therapy Effects in Peripheral Nerves Patient With Leprosy. Recruiting NCT03072004 Not Applicable
36 IVIg Treatment-Related Fluctuations in CIDP Patients Using Daily Grip Strength Measurements Active, not recruiting NCT02414490 Intravenous Immunoglobulin
37 Subcutaneous Immunoglobulin for CIDP Active, not recruiting NCT02465359 Not Applicable Immune Globulin Subcutaneous (Human)
38 Descriptive Analysis of Morphological Aspects of Nerve by Ultra-high Frequency Ultrasound (30-50MHZ) in Demyelinating Neuropathies: Inflammatory Demyelinating Polyneuropathy Chronic (IPDC), Neuropathy Multifocal Motor Block of Conducting (NMMBC) and Neuro Not yet recruiting NCT03008733 Not Applicable
39 Quantification of Nerve Stiffness in Neuropathies Not yet recruiting NCT03397303 Not Applicable
40 Randomized Study of Plasmapheresis or Human Immunoglobulin Infusion in Childhood Guillain-Barre Syndrome Terminated NCT00004833 Not Applicable Immune globulin

Search NIH Clinical Center for Demyelinating Polyneuropathy

Sources

Genetic Tests for Demyelinating Polyneuropathy

About this section
Sources

Anatomical Context for Demyelinating Polyneuropathy

About this section

MalaCards organs/tissues related to Demyelinating Polyneuropathy:

41
T Cells, Spinal Cord, B Cells, Brain, Skin, Liver, Endothelial
Sources

Publications for Demyelinating Polyneuropathy

About this section

Articles related to Demyelinating Polyneuropathy:

(show top 50) (show all 725)
# Title Authors Year
1
Inflammatory demyelinating polyneuropathy versus leptomeningeal disease following Ipilimumab. ( 29382383 )
2018
2
Chronic inflammatory demyelinating polyneuropathy misdiagnosis: A clinical more than electrophysiogical problem? ( 29406592 )
2018
3
Onset of fulminant type 1 diabetes mellitus under immunotolerance status after long-term therapy for chronic inflammatory demyelinating polyneuropathy. ( 29905029 )
2018
4
Cerebrospinal Fluid Cytokine Expression Profile in Multiple Sclerosis and Chronic Inflammatory Demyelinating Polyneuropathy. ( 29182448 )
2018
5
Octagam<sup>Ar</sup> for chronic inflammatory demyelinating polyneuropathy: results from three observational studies. ( 29517417 )
2018
6
A patient with peripheral demyelinating neuropathy, central dysmyelinating leukodystrophy, Waardenburg syndrome, and severe hypoganglionosis associated with a novel SOX10 mutation. ( 29681101 )
2018
7
Nocebo in chronic inflammatory demyelinating polyneuropathy; a systematic review and meta-analysis of placebo-controlled clinical trials. ( 29627036 )
2018
8
A novel paraneoplastic syndrome with acquired lipodystrophy and chronic inflammatory demyelinating polyneuropathy in an adolescent male with craniopharyngioma. ( 29455190 )
2018
9
Vestibular impairment in chronic inflammatory demyelinating polyneuropathy. ( 29260355 )
2018
10
Elevated serum levels of endothelin-1 in patients with chronic inflammatory demyelinating polyneuropathy. ( 29137897 )
2018
11
Standing postural reaction to visual and proprioceptive stimulation in chronic acquired demyelinating polyneuropathy. ( 29313871 )
2018
12
Corticosteroids in chronic inflammatory demyelinating polyneuropathy : A retrospective, multicentre study, comparing efficacy and safety of daily prednisolone, pulsed dexamethasone, and pulsed intravenous methylprednisolone. ( 29968199 )
2018
13
Differences between acute-onset chronic inflammatory demyelinating polyneuropathy and acute inflammatory demyelinating polyneuropathy in adult patients. ( 29603827 )
2018
14
Transthyretin amyloid polyneuropathies mimicking a demyelinating polyneuropathy. ( 29907605 )
2018
15
Subcutaneous IgG for chronic inflammatory demyelinating polyneuropathy. ( 29122522 )
2018
16
Neurofascin and Compact Myelin Antigen-Specific T Cell Response Pattern in Chronic Inflammatory Demyelinating Polyneuropathy Subtypes. ( 29615965 )
2018
17
Elevated leukocyte count in cerebrospinal fluid of patients with chronic inflammatory demyelinating polyneuropathy. ( 29341326 )
2018
18
Possible Combined Central and Peripheral Demyelination Presenting as Optic Neuritis, Cervical Myelitis, and Demyelinating Polyneuropathy with Marked Nerve Hypertrophy. ( 29540658 )
2018
19
Bilateral facial nerve palsies secondary to chronic inflammatory demyelinating polyneuropathy following adalimumab treatment. ( 29179036 )
2018
20
The ulnar ratio as a sensitive and specific marker of acute inflammatory demyelinating polyneuropathy. ( 29940481 )
2018
21
Drug-induced hypersensitivity syndrome followed by chronic inflammatory demyelinating polyneuropathy. ( 29671897 )
2018
22
High-resolution nerve ultrasound and magnetic resonance neurography as complementary neuroimaging tools for chronic inflammatory demyelinating polyneuropathy. ( 29552093 )
2018
23
Autoantibodies Against the Node of Ranvier in Seropositive Chronic Inflammatory Demyelinating Polyneuropathy: Diagnostic, Pathogenic, and Therapeutic Relevance. ( 29867996 )
2018
24
Does grip strength reflect isokinetic muscle strength in lower limbs in patients with chronic inflammatory demyelinating polyneuropathy? ( 29603302 )
2018
25
Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. ( 29122523 )
2018
26
Chronic inflammatory demyelinating polyneuropathy: evaluation of the vestibular system with cervical and ocular vestibular evoked myogenic potentials. ( 29700616 )
2018
27
Challenges in the diagnosis of chronic inflammatory demyelinating polyneuropathy. ( 29541543 )
2018
28
Outcome in chronic inflammatory demyelinating polyneuropathy from a Malaysian centre over sixteen years. ( 29398193 )
2018
29
Utility of Neurological Imaging in Sensory Variant of Chronic Inflammatory Demyelinating Polyneuropathy: A Case Report. ( 28221307 )
2017
30
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): An Uncommon Manifestation of Systemic Lupus Erythematosus (SLE). ( 28894082 )
2017
31
Neuromuscular ultrasound findings in distal acquired demyelinating symmetric variant of chronic inflammatory demyelinating polyneuropathy. ( 28667663 )
2017
32
ELectron microscopic abnormality and therapeutic efficacy in chronic inflammatory demyelinating polyneuropathy with anti-neurofascin155 immunoglobulin G4 antibody. ( 28796305 )
2017
33
Drug-induced cutaneous lupus erythematosus after immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a case series. ( 28480635 )
2017
34
Myasthenia gravis and chronic inflammatory demyelinating polyneuropathy in the same patientA -A a case report. ( 29073825 )
2017
35
Role of &amp;quot;Sural Sparing&amp;quot; Pattern (Absent/Abnormal Median and Ulnar with Present Sural SNAP) Compared to Absent/Abnormal Median or Ulnar with Normal Sural SNAP in Acute Inflammatory Demyelinating Polyneuropathy. ( 29085327 )
2017
36
Acute simultaneous development of brain tumour-like lesion and demyelinating polyneuropathy in a patient with chronic relapsing myelitis. ( 28795610 )
2017
37
Intravenous immunoglobulin for maintenance treatment of chronic inflammatory demyelinating polyneuropathy: a multicentre, open-label, 52-week phase III trial. ( 28768822 )
2017
38
Charcot-Marie-Tooth disease type 2 caused by homozygous MME gene mutation superimposed by chronic inflammatory demyelinating polyneuropathy. ( 28855494 )
2017
39
Gastroduodenal Burkitt Lymphoma Presenting as Demyelinating Polyneuropathy. ( 28532696 )
2017
40
Anti-Ma2-associated limbic encephalitis with coexisting chronic inflammatory demyelinating polyneuropathy in a patient with non-Hodgkin lymphoma: A case report. ( 28984777 )
2017
41
Nodopathy: chronic inflammatory demyelinating polyneuropathy with anti-neurofascin 155 antibodies. ( 28108521 )
2017
42
The Prevalence and Severity of Autonomic Dysfunction in Chronic Inflammatory Demyelinating Polyneuropathy. ( 28904461 )
2017
43
Electrodiagnostic misdiagnosis of chronic inflammatory demyelinating polyneuropathy: What are the problems? and how to right the wrongs. ( 29193155 )
2017
44
Acute demyelinating polyneuropathy induced by nivolumab. ( 28844069 )
2017
45
Diagnostic Value of the Near-Nerve Needle Sensory Nerve Conduction in Sensory Inflammatory Demyelinating Polyneuropathy. ( 28796344 )
2017
46
Demyelinating polyneuropathy in a case of anti-LGI1 encephalitis. ( 28073143 )
2017
47
Predominant Upper Limb Chronic Demyelinating Polyneuropathy Associated with HBV Infection. ( 29610592 )
2017
48
Autoantibodies to nodal isoforms of neurofascin in chronic inflammatory demyelinating polyneuropathy. ( 28575198 )
2017
49
Quantitative muscle ultrasound is useful for evaluating secondary axonal degeneration in chronic inflammatory demyelinating polyneuropathy. ( 29075571 )
2017
50
Chronic Inflammatory Demyelinating Polyneuropathy: A Case Series. ( 29143254 )
2017
Sources

Variations for Demyelinating Polyneuropathy

About this section
Sources

Expression for Demyelinating Polyneuropathy

About this section
Search GEO for disease gene expression data for Demyelinating Polyneuropathy.
Sources

Pathways for Demyelinating Polyneuropathy

About this section

Pathways related to Demyelinating Polyneuropathy according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Neuroscience 4
11.79 CNTN2 MAG NFASC NGF
2
L1CAM interactions 66
Show member pathways
 11.43 CNTN1 CNTN2 NFASC
3
Cell adhesion molecules (CAMs) 37
11.08 CNTN1 CNTN2 MAG NFASC
4
FOXA2 and FOXA3 transcription factor networks 1
10.9 ALB TTR
Sources

GO Terms for Demyelinating Polyneuropathy

About this section

Cellular components related to Demyelinating Polyneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.95 ALB APOA4 CNTN1 HP NFASC PTGDS
2 extracellular space GO:0005615 9.85 ALB APOA4 HP NGF PTGDS TTR
3 blood microparticle GO:0072562 9.5 ALB APOA4 HP
4 node of Ranvier GO:0033268 9.26 CNTN2 NFASC
5 paranode region of axon GO:0033270 9.16 MAG NFASC
6 myelin sheath GO:0043209 9.02 ALB CNTN1 CNTN2 MAG NFASC
7 compact myelin GO:0043218 8.96 MAG PMP22

Biological processes related to Demyelinating Polyneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell adhesion GO:0007155 9.71 CNTN1 CNTN2 MAG NFASC
2 cellular protein metabolic process GO:0044267 9.54 ALB APOA4 TTR
3 receptor-mediated endocytosis GO:0006898 9.5 ALB FCGR2B HP
4 high-density lipoprotein particle remodeling GO:0034375 9.26 ALB APOA4
5 central nervous system myelination GO:0022010 9.16 CNTN2 MAG
6 protein localization to juxtaparanode region of axon GO:0071205 8.96 CNTN2 NFASC
7 peripheral nervous system development GO:0007422 8.8 NFASC NGF PMP22

Molecular functions related to Demyelinating Polyneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 carbohydrate binding GO:0030246 9.33 CNTN1 CNTN2 MAG
2 fatty acid binding GO:0005504 8.96 ALB PTGDS
3 antioxidant activity GO:0016209 8.8 ALB APOA4 HP
Sources

Sources for Demyelinating Polyneuropathy

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....